Gina Mauro | Authors


Prior Local Treatment Does Not Impact Survival Benefit of Enzalutamide/ADT in mHSPC

May 14, 2022

Results from a post-hoc analysis of ARCHES showed that the enzalutamide plus ADT significantly improved survival, as well as key secondary end points, compared with placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Upfront Olaparib/Abiraterone Achieves Significant rPFS Benefit in mCRPC

February 18, 2022

A significant percentage of reduction in the risk of radiographic disease progression or death was observed with olaparib plus abiraterone compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer.